Heparin-derived heparan sulfate mimics to modulate heparan sulfate-protein interaction in inflammation and cancer

Matrix Biology

Volumn 29, Issue 6, 2010, Pages 442-452

  Casu, Benito ^a   Naggi, Annamaria ^a   Torri, Giangiacomo ^a  

^a Istituto di Ricerche Chimiche e Biochimiche G Ronzoni   (Italy)

Author keywords

Cancer; Chemokines; Cytokines; Glycotherapeutics; Heparan sulfates; Heparin binding proteins; Heparins; Inflammation

Indexed keywords

FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; HEPARAN SULFATE; HEPARANASE; HEPARIN; INTERLEUKIN 8; LOW MOLECULAR WEIGHT HEPARIN;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; BIOLOGICAL ACTIVITY; COMPLEX FORMATION; DIMERIZATION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME SPECIFICITY; HUMAN; INFLAMMATION; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; SEQUENCE ANALYSIS; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTICOAGULANTS; ANTIMICROBIAL CATIONIC PEPTIDES; BLOOD PROTEINS; CARRIER PROTEINS; EXTRACELLULAR MATRIX; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; GLUCURONIDASE; HEPARAN SULFATE PROTEOGLYCANS; HEPARIN; HEPARITIN SULFATE; HUMANS; INFLAMMATION; INTERLEUKIN-8; MODELS, MOLECULAR; NEOPLASMS; OLIGOSACCHARIDES; POLYSACCHARIDES; PROTEINS;

EID: 77956485588     PISSN: 0945053X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.matbio.2010.04.003     Document Type: Review

References (114)

1. Ai X., Do A.-T., Kusche-Gullberg M., Lindahl U., Lu K., Emerson C.P. Substrate specificity and domain functions of extracellular heparan sulfate 6-O-endosulfatases, QSulf1 and QSulf2. J. Biol. Chem. 2006, 281:4969-4976.
2. Angulo J., Ojeda R., de Paz J.-L., Lucas R., Nieto P.M., Lozano R.M., Recondo-Horcajo M., Giménez-Gallego G., Martín-Lomas M. The activation of fibroblast growth factors (FGFs) by glycosaminoglycans: influence of the sulfation pattern on the biological activity of FGF1. ChemBioChem 2004, 5:55-61.
3. Arungundram S., Al-Mafraji K., Asong J., Leach F.E.I.I.I., Amster J., Venot A., Thurnbull J.E., Boons G.-J. Modular synthesis of heparan sulfate oligosaccharides for structure-activity relationship studies. J. Am. Chem. Soc. 2009, 131:17394-17405.
4. Asada M., Shinomiya M., Suzuki M., Honda E., Sugimoto R., Ikekita M., Imamura T. Glycosaminoglycan affinity of the complete fibroblast growth factor family. Biochim. Biophys. Acta 2009, 1790:40-48.
5. Ashikari-Hada S., Habuchi H., Karyia Y., Ytoh H., Reddi A.H., Kimata K. Characterization of growth factor-binding structures in heparin/heparan sulfate using an octasaccharide library. J. Biol. Chem. 2004, 279:12346-12354.
6. Bernfield M., Götte M., Park P.W., Reizes O., Fitzgerald M.L., Lincecum J., Zako M. Functions of cell surface proteoglycans. Annu. Rev. Biochem. 1999, 68:729-777.
7. Bishop J.R., Schuksz M., Esko J.D. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 2007, 446:1030-1037.
8. Bisio A., Mantegazza A., Urso E., Naggi A., Torri G., Viskov C., Casu B. High-performance liquid chromatographic/mass spectrometric studies on the susceptibility of heparin species to cleavage by heparanase. Semin. Thromb. Hemost. 2007, 33(5):488-495.
9. Borsig L. Selectins facilitate carcinoma metastasis and heparin can prevent them. News Physiol. Sci. 2004, 19:16-21.
10. Borsig L., Wong R., Hynes R.O., Varki N.M., Varki A. Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc. Natl. Acad. Sci. 2002, 99:2193-2198.
11. Bourin M.-C., Lindahl U. Glycosaminoglycans and the regulation of blood coagulation. Biochem. J. 1993, 289:313-330.
12. Capila I., Linhardt R.J. Heparin-protein interactions. Angew. Chem. Int. Ed. 2002, 41:390-412.
13. Casu B. Structure and active domains of heparin. Chemistry and Biology of Heparin and Heparan Sulfate 2005, 1-28. Elsevier, Amsterdam. H.G. Garg, R.J. Linhardt, C.A. Hales (Eds.).
14. Casu B., Lindahl U. Structure and biological interactions of heparin and heparan sulfate. Adv. Carbohydr. Chem. Biochem. 2001, 57:159-206.
15. Casu B., Petitou M., Provasoli M., Sinaÿ P. Conformational flexibility: a new concept for explaining binding and biological properties of iduronic acid-containing glycosaminoglycans. Trends Biochem. Sci. 1988, 13:221-225.
16. Casu B., Guerrini M., Naggi A., Perez M., Torri G., Ribatti D., Carminati P., Giannini G., Penco S., Pisano C., Belleri M., Rusnati M., Presta M. Short heparin sequences spaced by glycol-split uronate residues are antagonists of fibroblast growth factor 2 and angiogenesis inhibitors. Biochemistry 2002, 41:10519-10528.
17. Casu B., Guerrini M., Guglieri S., Naggi A., Perez M., Torri G., Cassinelli G., Ribatti D., Carminati P., Giannini G., Penco S., Pisano C., Belleri M., Rusnati M., Presta M. Undersulfated and glycol-split heparins endowed with antiangiogenic activity. J. Med. Chem. 2004, 47:838-848.
18. Casu B., Vlodavsky I., Sanderson R.D. Non-anticoagulant heparins and inhibition of cancer. Pathophysiol. Haemost. Thromb. 2008, 36:195-203.
19. Conrad H.E. Heparin Binding Proteins 1998, Academic Press, San Diego.
20. Coombe D.R. Biological implications of glycosaminoglycan interactions with haemopoietic cytokines. Immunol. Cell Biol. 2008, 86:598-607.
21. Coombe D.R., Kett W.C. Heparan sulfate-protein interactions: therapeutic potential through structure-function insights. Cell. Mol. Life Sci. 2005, 62:410-424.
22. De Paz J.L., Moseman E.A., Noti C., Polito L., van Andrian U.H., Seeberger P.H. Profiling heparin-chemokine interactions using synthetic tools. ACS Chem. Biol. 2007, 2:735-744.
23. Deakin J.A., Blaum B.S., Gallagher J.T., Lyon M. The binding properties of minimal oligosaccharides reveal a common heparan sulfate-binding site in hepatocyte growth factor/scatter factor that can accommodate a variety of sulfation patterns. J. Biol. Chem. 2009, 284:6311-6321.
24. Delehedde M., Lyon M., Gallagher J.T., Rudland P.S., Fernig D.G. Fibroblast growth factor-2 binds to small heparin-derived oligosaccharides and stimulates a sustained phosphorylation of p42/44 mitogen-activated protein kinase and proliferation of rat mammary fibroblasts. Biochem. J. 2002, 366:235-244.
25. Dreyfuss J.L., Regatieri C., Jarrouge T.R., Cavalheiro R.P., Sampajo L.O., Nader H.B. Heparan sulfate proteoglycans: structure, protein interactions and cell signaling. Ann. Braz. Acad. Sci. 2009, 81:409-4299.
26. Fears C.Y., Woods A. The role of syndecans in diseases and wound healing. Matrix Biol. 2006, 25:443-456.
27. Ferro V., Hammond E., Fairweather J.K. The development of inhibitors of heparanase, a key enzyme in tumor metastasis, angiogenesis and inflammation. Mini Rev. Med. Chem. 2004, 4:693-702.
28. Folkman J., Langer R., Linhardt R.J., Haudenschild C., Taylor S. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 1983, 221:719-725.
29. Forsten-Williams K., Chu C.L., Fannon M., Buczek-Thomas J.A., Nugent M.A. Control of growth factor networks by heparan sulfate proteoglycans. Ann. Biochem. Eng. 2008, 36:2134-2148.
30. Fux L., Ilan N., Sanderson R.D., Vlodavsky I. Heparanase: busy at the cell surface. Trends Biochem. Sci. 2009, 34:511-519.
31. Gallagher J.T. Multiprotein signaling complexes: regional assembly on heparan sulphate. Biochem. Soc. Trans. 2006, 34:438-441.
32. Gandhi N.S., Mancera R.L. The structure of glycosaminoglycans and their interactions with proteins. Chem. Biol. Drug Des. 2008, 72:455-482.
33. Goger B., Halden Y., Rek R., Mösl D., Pye J., Gallagher J., Kungl A.J. Different affinities of glycosaminoglycan oligosaccharides for monomeric and dimeric interleukin-8: a model for chemokine regulation at inflammatory sites. Biochemistry 2002, 41:1640-1646.
34. Goodger S.J., Robinson C.J., Murphy K.J., Gasiunas N., Harmer N.J., Blundell T.L., Pye D.A., Gallagher J.T. Evidence that heparin saccharides promote FGF2 mitogenesis through two distinct mechanisms. J. Biol. Chem. 2008, 283:13001-13008.
35. Götte M. Syndecans in inflammation. FASEB J. 2003, 17:575-591.
36. Guerrini M., Guglieri S., Casu B., Torri G., Mourier P., Boudier C., Viskov C. Antithrombin-binding octasaccharides and role of extensions of the active pentasaccharide sequence in the specificity and strength of interaction. J. Biol. Chem. 2008, 283:26662-26675.
37. Guglieri S., Hricovíni, Raman R., Polito L., Torri G., Casu B., Sasisekharan R., Guerrini M. Minimum FGF2 binding structural requirements of heparin and heparan sulfate oligosaccharides as determined by NMR spectroscopy. Biochemistry 2008, 47:13862-13869.
38. Guimond S.E., Puvirajesinghe T.M., Skidmore M.A., Kalus I., Dierks T., Yates E.A., Turnbull J.E. Rapid purification and high sensitivity analysis of heparan sulfate from cells and tissues: toward glycomics profiling. J. Biol. Chem. 2009, 284:25714-25722.
39. Harmer N.J., Robinson C.J., Adam L.E., Ilag L.L., Robinson C.V., Gallagher J.T., Blundell T.L. Multimers of the fibroblast growth factor (FGF)-FGF receptor-saccharide complex are formed on long oligomers of heparin. Biochem. J. 2006, 393:741-748.
40. Hasan J., Shnyder S.D., Clamp A.R., McGown A.T., Bicknell R., Presta M., Bibby M., Double J., Craig S., Leeming D., Stevenson K., Gallagher J.T., Yayson G.C. Heparin octasaccharides inhibit angiogenesis in vivo. Clin. Cancer Res. 2005, 11:8172-8179.
41. Hostetter N., Naggi A., Torri G., Ishai-Michaeli R., Casu B., Vlodavsky I., Borsig L. P-selectin and heparanase-dependent antimetastatic activity of non-anticoagulant heparins. FASEB J. 2007, 21:3562-3572.
42. Imberty A., Lortat-Jacob H., Pérez S. Structural view of glycosaminoglycan-protein interactions. Carbohydr. Res. 2007, 342:430-439.
43. Iozzo R.V. Basement membrane proteoglycans: from cellar to ceiling. Nat. Rev., Mol. Cell. Biol. 2005, 6:646-656.
44. Iozzo R.V., San Antonio J.D. Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J. Clin. Invest. 2001, 108:349-355.
45. Iozzo R.V., Zoeller J.J., Nyström A. Basement membrane proteoglycans: modulators par excellence of cancer growth and angiogenesis. Mol. Cells 2009, 27:503-513.
46. Jemth P., Kreuger J., Kusche-Gullberg M., Sturiale L., Giménez-Gallego G., Lindahl U. Biosynthetic oligosaccharide libraries for identification of protein-binding heparan sulfate motifs. Exploring the structural diversity by screening for fibroblast growth factor FGF1 and FGF2 binding. J. Biol. Chem. 2002, 277:30567-30573.
47. Johnson Z., Proudfoot A.E., Handel T.M. Interaction of chemokines and glycosaminoglycans: a new twist in the regulation of chemokines function with opportunities for therapeutic intervention. Cytokine Growth Factor Rev. 2005, 16:625-636.
48. Koenig A., Norgard-Sumnicht K., Linhardt R., Varki A. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J. Clin. Invest. 1998, 101:877-889.
49. Korir A.K., Larive K. Advances in the separation, sensitive detection, and characterization of heparin and heparan sulfate. Anal. Bioanal. Chem. 2009, 393:155-169.
50. Kreuger J., Salmivirta M., Sturiale L., Giménez-Gallego G., Lindahl U. Sequence analysis of heparan sulfate epitopes with graded affinities for fibroblast growth factors 1 and 2. J. Biol. Chem. 2001, 276:30744-30752.
51. Kreuger J., Spillmann D., Li J.-P., Lindahl U. Interactions between heparan sulfate and proteins: the concept of specificity. J. Biol. Chem. 2006, 174:323-327.
52. Krieger E., Geretti E., Brandner B., Goger B., Wells T.N., Kungl A.J. A structural and dynamic model for the interaction of interleukin-8 and glycosaminoglycans: support from isothermal fluorescence titrations. Proteins 2004, 54:768-775.
53. Laremore T.N., Zhang F., Dordick J.S., Linhardt R.J. Recent progresses and applications in glycosaminoglycan and heparin research. Curr. Opin. Chem. Biol. 2009, 13:633-640.
54. Lazo-Langner A., Goss G.D., Spaans J.N., Rodger M.A. The effect of low-molecular- weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J. Thromb. Haemost. 2007, 5:729-737.
55. Lee Y.D., Lee S.W., Kim S.K., Lee M., Chang H.W., Moon H.T., Byun Y., Kim S.Y. Antiangiogenic activity of orally absorbable heparin derivative in different types of cancer cells. Pharm. Res. 2009, 26:2667-2676.
56. Lever R., Page C.P. Novel drug development opportunities for heparin. Nat. Rev. Drug Discov. 2002, 1:140-148.
57. Li J.-P., Vlodavsky I. Heparin, heparan sulfate and heparanase in inflammatory reactions. Thromb. Haemost. 2009, 102(3):823-828.
58. Lindahl U. Heparan sulfate-protein interactions-a concept for drug design?. Thromb. Haemost. 2007, 98:109-115.
59. Lindahl U., Li J.-P. Interaction between heparan sulfate and proteins - design and functional implications. Int. Rev. Cell Biol. 2009, 276:105-159.
60. Lindahl U., Kusche-Gullberg M., Kjellén L. Regulated diversity of heparan sulfate. J. Biol. Chem. 1998, 273:24979-24982.
61. Lindahl U., Li J., Kusche-Gullberg M., Salmivirta M., Alaranta S., Veromaa T.-, Emeis J., Roberts I., Taylor C., Oreste P., Zoppetti G., Naggi A., Torri G., Casu B. Generation of "neoheparin" from E. coli capsular polysaccharide. J. Med. Chem. 2005, 48:349-352.
62. Linhardt R.J. Heparin: structure and activity. J. Med. Chem. 2003, 46:2551-2564.
63. Liu D., Sasisekharan R. Role of heparan sulfate in cancer. Chemistry and Biology of Heparin and Heparan Sulfate 2005, 699-725. Elsevier, Amsterdam. A.G. Garg, R.J. Linhardt, C.A. Hales (Eds.).
64. Liu D., Shriver Z., Venkataraman G., El Shabrawi Y., Sasisekharan R. Tumor cell surface heparan sulfate as cryptic promoters or inhibitors of tumor growth and metastasis. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:568-573.
65. Lortat-Jacob H. The molecular basis and functional implications of chemokine interactions with heparan sulphate. Curr. Opin. Struct. Biol. 2009, 19:543-548.
66. Lundin L., Larsson H., Kreuger J., Kanda S., Lindahl U., Salvimirta M., Claesson-Welsh L. Selectively desulfated heparin inhibits fibroblast growth factor-induced mitogeneity and angiogenesis. J. Biol. Chem. 2000, 275:24653-24660.
67. Lyon M., Gallagher J.T. Biospecific sequences and domains in heparan sulphate and the regulation of cell growth and adhesion. Matrix Biol. 1998, 17:485-493.
68. Martin J.G., Gupta M., Xu Y., Akella S., Liu J., Dordick J.S., Linhardt R.J. Toward an artificial Golgi: redisigning the biological activities of heparan sulfate on a digital microfluid chip. J. Am. Chem. Soc. 2009, 131:11041-11048.
69. Merry C.L., Lyon M., Deakin J.A., Hopwood J.J., Gallagher J.T. Highly sensitive sequencing of the sulfated domains of heparan sulfate. J. Biol. Chem. 1999, 274:18455-18462.
70. 15N-NMR relaxation studies. Glycoconj. J. 2008, 25:401-414.
71. Mousa S.A., Linhardt R., Francis J.L., Amirkhosravi A. Anti-metastatic effect of a non-anticoagulant low-molecular weight heparin versus the standard low-molecular-weight heparin, enoxaparin. Thromb. Haemost. 2006, 96:816-821.
72. Mohammadi M., Olsen S.K., Ibrahimi O.A. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev. 2005, 16:107-137.
73. Mulloy B., Forster M.J. Application of drug discovery software to the identification of heparin-binding sites on protein surfaces: a computational survey of the 4-helix cytokines. Mol. Simul. 2008, 34:381-389.
74. Mulloy B., Forster M.J., Jones C., Davies D.B. NMR and molecular modeling studies in the solution conformation of heparin. Biochem. J. 1993, 293:849-858.
75. Murphy K.J., Merry C.L.R., Lyon M., Thompson J.E., Roberts I.S., Gallagher J.T. A new model for the domain structure of heparan sulfate based on the novel specificity of K5 lyase. J. Biol. Chem. 2004, 279:27239-27245.
76. Murphy K.J., McLay N., Pye A. Structural studies of heparan sulfate hexasaccharides: new insights into iduronate conformational behaviour. J. Am. Chem. Soc. 2008, 130:12435-12444.
77. Naggi A. Glycol-splitting as a device for modulating inhibition of growth factors and heparanase by heparin and heparin derivatives. Chemistry and Biology of Heparin and Heparan Sulfate 2005, 461-481. Elsevier, Amsterdam. H.G. Garg, R.J. Linhardt, C.A. Hales (Eds.).
78. Naggi A., Casu B., Perez M., Torri G., Cassinelli G., Penco S., Pisano C., Giannini G., Ishai-Michaeli R., Vlodavsky I. Modulation of heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol-splitting. J. Biol. Chem. 2005, 280:12103-12113.
79. Okada Y., Yamada S., Toyoshima M., Dong J., Nakajima M., Sugahara K. Structural recognition by recombinant human heparanase that plays critical roles in tumor metastasis. J. Biol. Chem. 2002, 277:42488-42495.
80. Parish C.R. The role of heparan sulphate in inflammation. Nat. Rev. Immunol. 2006, 6:633-643.
81. Peterson S., Frick A., Liu J. Design of biologically active heparan sulfate and heparin using an enzyme-based approach. Nat. Prod. Rep. 2009, 26:610-627.
82. Petitou, M., Driguez, P.A., 2006. Azasugar derivatives, heparanase inhibitors. Eur. Patent CO7H5/06;CO7H3/06. US Appl. US 20070625994 20070123.
83. Pisano C., Aulicino C., Vesci L., Casu B., Naggi A., Torri G., Ribatti D., Belleri M., Rusnati M., Presta M. Undersufated, low-molecular weight glycol-split heparin as an antiangiogenic VEGF antagonist. Glycobiology 2005, 15:1C-6C.
84. Powell A.K., Yates E.A., Fernig D.G., Turnbull J.E. Interactions of heparin/heparan sulfate with proteins: appraisal of structural factors and experimental approaches. Glycobiology 2004, 14:17R-30R.
85. Presta M., Dell'Era P., Mitola S., Moroni E., Ronca R., Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 2005, 16:159-178.
86. Purushothaman A., Uyama T., Kobayashi F., Yamada S., Sugahara K., Rapraeger A.C., Sanderson R.D. Heparanase enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood 2010, 115:2449-2457.
87. Pye D.A., Vivès R.R., Hyde P., Gallagher J.T. Regulation of FGF-1 mitogenic activity by heparan sulfate oligosaccharides is dependent on specific structural features: differential requirements for the modulation of FGF-1 and FGF-2. Glycobiology 2000, 10:1183-1192.
88. Raman R., Venkataraman G., Ernst S., Sasisekharan V., Sasisekharan R. Structural specificity of heparin binding in the fibroblast growth factor family of proteins. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:2357-2362.
89. Reiland J., Sanderson R.D., Waguespack M., Barker S.A., Long R., Carson D.D., Marchetti D. Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion. J. Biol. Chem. 2004, 279:8047-8055.
90. Rek A., Krenn E., Kungl A.J. Therapeutically targeting protein-glycan interactions. Brit. J. Pharmacol. 2009, 157:686-694.
91. Robinson C.J., Harmer N.J., Goodger S.J., Blundell T.L., Gallagher J. Cooperative dimerization of fibroblast growth factor 1 (FGF1) upon a single heparin saccharide may drive the formation of 2:2:1 FGF1-FGFR2c-heparin ternary complexes. J. Biol. Chem. 2005, 280:42274-42282.
92. Robinson C.J., Mulloy B., Gallagher G.T., Stringer S.E. VEGF 165-binding sites within heparan sulfate encompass two highly sulfated domains and can be liberated by K5 lyase. J. Biol. Chem. 2006, 281:1731-1740.
93. Rudd T.R., Yates E.A., Hricovíni M. Spectroscopic and theoretical approaches for the determination of heparin saccharide structure and the study of protein-glycosaminoglycan complexes in solution. Curr. Med. Chem. 2009, 16:4750-4766.
94. Sandbäck-Pikas D., Li J.-P., Vlodavsky I., Lindahl U. Substrate specificity of heparanases from human hepatoma and platelets. J. Biol. Chem. 1998, 273:18770-18777.
95. Sanderson R.D., Yang Y. Syndecan-1: a dynamic regulator of the myeloma microenvironment. Clin. Exp. Metastasis 2008, 25:149-159.
96. Sasisekharan R., Raman R., Prabhakar V. Glycomics approach to structure-function relationships of glycosaminoglycans. Ann. Rev. Biomed. Eng. 2006, 8:181-231.
97. Schenauer M.R., Yu Y., Sweeney M.D., Leary J.A. CCR2 chemokines bind selectively to acetylated heparan sulfate octasaccharides. J. Biol. Chem. 2007, 282:25182-25188.
98. Schenauer M.R., Meissen J.K., Seo Y., Ames J.B., Leary J.A. Heparan sulfate separation, sequencing, and isomeric differentiation: ion mobility spectrometry reveals specific iduronic acid and glucuronic acid-containing hexasaccharides. Anal. Chem. 2009, 81:10179-10185.
99. Seeberger P.H., Werz D.B. Synthesis and medical applications of oligosaccharides. Nature 2008, 446:1046.
100. Skidmore M.A., Guimond S.E., Rudd T.R., Ferning D.G., Turnbull J.E., Yates E.A. The activities of heparan sulfate and its analogue heparin are dictated by biosynthesis, sequence, and conformation. Connective Tissue Res. 2008, 49:140-144.
101. Spillmann D., Witt D., Lindahl U. Defining the interleukin-8-binding domain of heparan sulfate. J. Biol. Chem. 1998, 273:15487-15493.
102. Taylor K.L., Gallo R.L. Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation. FASEB J. 2006, 20:9-22.
103. Van Boekel C.A.A., Petitou M. The unique antithrombin III binding domain of heparin: a lead of new synthetic antithrombotics. Angew. Chem. Int. Ed. 1993, 32:1671-1690.
104. Vlodavsky I., Ilan N., Naggi A., Casu B. Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr. Pharm. Des. 2007, 13:2057-2073.
105. Vlodavsky I., Elkin M., Abboud-Jarrous G.-, Levi-Adams F., Fuks L., Shafat I., Ilan N. Heparanase: one molecule with multiple functions in cancer progression. Connective Tissue Res. 2008, 49:207-210.
106. Waern I., Jia J., Pejler G., Zcharia E., Vlodavsky I., Li J.-P., Wernersson S. Accumulation of Ym1 and formation of intracellular crystalline bodies in alveolar macrophages lacking heparanase. Mol. Immunol. 2010, 47:1467-1475.
107. Wang L., Fuster M., Sriramarao P., Esko J.D. Endothelial heparan sulfate deficiency impairs L-selectin- and chemokine-mediated neutrophil trafficking during inflammatory responses. Nat. Immunol. 2005, 6:902-910.
108. Whitelock J.M., Iozzo R.V. Heparan sulfate: a complex polymer charged with biological activity. Chem. Rev. 2005, 105:2745-2764.
109. Whitelock J.M., Melrose J., Iozzo R.V. Diverse cell signaling events modulated by perlecan. Biochemistry 2008, 47:11174-11183.
110. Yang Y., Mcleod V., Miao H.Q., Theus A., Zhan F., Shaughnessy J.D., Sawyer J., Li J.-P., Zcharia E., Vlodavsky I., Sanderson R.D. Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J. Biol. Chem. 2007, 282:13326-13333.
111. Yang Y., McLeod V., Day Y., Khotskaya-Sample Y., Shriver Z., Venkataraman G., Sasisekharan R., Naggi A., Torri G., Casu B., Vlodavsky I., Suva L.J., Epstein J., Yacobby S., Shaughnessy J.D., Bartologie B., Sanderson R.D. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood 2007, 110:2041-2048.
112. Yip G.W., Smollich M., Götte M. Therapeutic value of glycosaminoglycans in cancer. Mol. Cancer Ther. 2006, 5:2139-2148.
113. Young E. The anti-inflammatory effects of heparin and related compounds. Thromb. Res. 2008, 122:743-752.
114. Zhang F., Zhang Z., Lin X., Mohammadi M., Linhardt R.J. Compositional analysis of heparin/heparan sulfate interaction with fibroblast growth factor·fibroblast growth factor receptor complexes. Biochemistry 2009, 48:8379-8386.